Fertility and Sterility
Volume 94, Issue 1 , Pages 138-143 , June 2010

Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review

Received 4 December 2008 ,Revised 23 January 2009 ,Accepted 16 February 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Hankey BF, Miller B, Curtis R, Kosary C. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr. 1994;16:7–14
  3. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–1729
  4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–1144
  6. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology—v.2. 2008;Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed on September 16, 2008
  7. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559–563
  8. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994;12:888–894
  9. Anders CK, Hsu DS, Broadwater G, Acharva CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26:3324–3330
  10. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–2370
  11. Cohen I, Speroff L. Premature ovarian failure: update. Obstet Gynecol Surv. 1991;46:156–162
  12. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9:466–472
  13. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am. 1998;27:989–06
  14. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–4183
  15. Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs. 2002;13:417–424
  16. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106:514–523
  17. Partridge AH, Winer EP. Fertility after breast cancer: questions abound. J Clin Oncol. 2005;23:4259–4261
  18. National Cancer Institute. Clinical Trials. Available at http://www.cancer.gov/clinicaltrials.
  19. Fox KR, Scialla J, Moore H. Preventing chemotherapy-associated amenorrhea (CRA) with leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol. 2003;22:13;(abstr 50)
  20. Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006;17:74–78
  21. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat. 2008;110:411–416
  22. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18:90–95
  23. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23:4347–4353
  24. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol. 2005;23:3858–3859
  25. Wildiers H, Neven P, Amant F, D'hooghe T, Paridaens R. Fertility preservation in (breast) cancer patients: is it safe?. J Clin Oncol. 2006;24:5335–5336
  26. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol. 2002;21:37a;(abstr 143)
  27. Yarnold JR, Bliss JM, Earl H, George D, Lawrence D, Mortazaviet SH, et al. Ovarian ablation in pre-menopausal women with early breast cancer prescribed 5 years tamoxifen or tamoxifen plus chemotherapy: results from the UK NCRI adjuvant breast cancer interantional trial of 2144 patients. J Clin Oncol. 2004;22(Suppl):11s;(abstr 535)
  28. Singh KL, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation, and the role of ovarian reserve testing. Hum Reprod Update. 2005;11:69–89
  29. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90:1635–1639
  30. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21:2583–2592
  31. Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril. 1995;64:991–994
  32. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–2931
  33. Mor V, Allen S, Malin M. The psychosocial impact of cancer on older versus younger patients and their families. Cancer. 1994;74:2118–2127
  34. Wenzel LB, Fairclough DL, Brady MJ, Cella D, Garrett KM, Kluhsman BC, et al. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer. 1999;86:1768–1774
  35. Compas BE, Stoll MF, Thomsen AH, Oppedisano G, Epping- Jordan JE, Krag DN. Adjustment to breast cancer: age-related differences in coping and emotional distress. Breast Cancer Res Treat. 1999;54:195–203

 M.R.S.C. has nothing to disclose. J.C.P. has nothing to disclose. D.L.G. has nothing to disclose. M.F.F. has nothing to disclose.

PII: S0015-0282(09)00474-9

doi: 10.1016/j.fertnstert.2009.02.055

Fertility and Sterility
Volume 94, Issue 1 , Pages 138-143 , June 2010

Article Tools